Edaravone in the Treatment of Optic Neuritis

Launched by FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY · Sep 11, 2022

Keywords

ClinConnect Summary

This clinical trial is studying a medication called edaravone to see if it can help improve vision in patients with a specific type of optic neuritis known as aquaporin-4 antibody-positive optic neuritis. Optic neuritis is an inflammation of the optic nerve, which can cause vision problems. Researchers believe that edaravone may help repair the damage to the nerve and enhance visual recovery in these patients.

To participate in this trial, you need to be at least 18 years old and have had your first symptoms of optic neuritis within the last 30 days. The trial is currently looking for Chinese patients who meet these criteria. If you join, you will receive edaravone and be monitored for its effects on your vision. Importantly, people with severe nearsightedness or certain eye conditions may not be eligible. This trial is an exciting opportunity to explore new treatments for improving vision in individuals affected by this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Chinese patients aged ≥18 with anti-aquaporin-4 antibody-positive optic neuritis
• • 2. Patients with a first episode of optic neuritis in either eye
• • 3. First symptoms of optic neuritis ≤30 days prior to the first administration of edaravone
• Exclusion Criteria:
• • 1. Myopia over 6 diopters
• • 2. Refractive media opacity affecting assessment of retinal layers and/or visual acuity